July 2022 FDA Recall Drug by Pine Pharmaceuticals, Llc
D-1514-2022 - Lack of Assurance of Sterility

This Class II drug recall was voluntarily initiated by Pine Pharmaceuticals, Llc on July 27, 2022 for the product Drug. The FDA reported the reason for recall as lack of assurance of sterility. The product was distributed in Product was distributed to direct accounts in AL, CA, NC and NY and the recall is currently terminated.

Recall Number: D-1514-2022

Reason for Recall
Lack of Assurance of Sterility
Initiated
07-27-2022
Reported
09-21-2022
Quantity
a) 920 syringes; b) 3263 syringes

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Pine Pharmaceuticals, LLC
Product was distributed to direct accounts in AL, CA, NC and NY
Bupivacaine HCl 0.375% w/v and Lidocaine HCl 2% w/v Solution for Retrobulbar or Peribulbar Injection; packaged in a) 10 mL prefilled syringe, Item# 803, barcode 6919408031; b) 5 mL prefilled syringe, Item# 933, barcode 6919409331, Rx only, Pine Pharmaceuticals, 355 Riverwalk Parkway, Tonawanda, NY 14150.

Batch or Lot Expiration Information

Lot# s: a) 58366, exp. date 09/26/2022; 60247, exp. date 12/04/2022; b) 54825, exp. date 08/10/2022; 57583, exp. date 08/22/2022; 59343, exp. date 10/30/2022; 60355, exp. date 10/11/2022